GLOPRIL Tablet

Hypertension: GLOPRIL-10 is indicated for the treatment of hypertension. It may be used alone as initial therapy or concomitantly with other classes of antihypertensive agents.

Heart Failure: GLOPRIL-10 is indicated as adjunctive therapy in the management of heart failure in patients who are not responding adequately to diuretics and digitalis.

Acute Myocardial Infarction: GLOPRIL-10 is indicated for the treatment of haemodynamically stable patients within 24 hours or acute myocardial infarction, to improve survival. Patients should receive, as appropriate, the standard recommended treatments such as thrombolytics, aspirin and beta-blockers.

Dosage

Adults: Initial: 10mg/day, maximum daily dose 40mg.

Elderly: Initial: 2.5-5mg/day, maximum daily dose 40mg.

Hypersensitivity to lisinopril or any component or other ACE inhibitors.

Fast or uneven heart beat, palpitations, or chest pain; fever or chills; numbness or tingling in your fingers or toes; skin rash, itching; swelling of your face, lips, or tongue.

Lithium: Increased serum lithium levels and symptoms of toxicity may occur.

Digoxin: Increased plasma digoxin levels.

Antacids: Decreased bioavailability of ACEs. May be more likely lisinopril, separate administration times by 1-2 hours.

Check with your prescriber or health care professional if you get an attack of severe diarrhea, nausea and vomiting, or if you sweat a lot. The loss of body fluid can make it dangerous to take lisinopril.

Avoid salt substitutes or other foods or substances high in potassium salts.

Lisinopril inhibits Angiotensin-Converting Enzyme (ACE) in human subjects and animals. ACE is a peptidyl dipeptidase that catalyzes the conversion of angiotensinⅠto the vasoconstrictor substance, angiotensinⅡ. AngiotensinⅡalso stimulates aldosterone secretion by the adrenal cortex. The beneficial effects of lisinopril in hypertension and heart failure appear to result primarily from suppression of the renin-angiotensin-aldosterone system. Inhibition of ACE results in decreased plasma angiotensinⅡwhich leads to decreased vasopressor activity and to decreased aldosterone secretion.